Home › Psychotic Disorders › NCT07417904
BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis
Young Adults and Violent Behavior During Early Psychosis (Aim 3)
Who can join
Ages 16 to 30 · All sexes
Full eligibility criteria
Inclusion Criteria: * Young adults aged 16-30 years * Diagnosis of early psychosis * Currently receiving outpatient care through an early psychosis clinic * Psychiatrically stable and deemed appropriate for participation by a treating clinician * Able and willing to provide informed consent Exclusion Criteria: * Unable to provide informed consent * Not fluent in English * History of antisocial behavior, as assessed at baseline * Immediate risk requiring a higher level of care
About the study
This study evaluates the feasibility and acceptability of BRAVE, a manualized cognitive behavioral therapy (CBT)-based intervention designed to address dynamic risk factors for violence among young adults with early psychosis. Using a stepped-wedge randomized design, all participants will receive treatment as usual followed by the BRAVE intervention. The study will also explore changes in violence-related behaviors and treatment engagement over time.
What is being tested
- BRAVE (Behavioral Response Against Violence Engagement) (behavioral)
- Treatment As Usual (TAU) (other)
Sponsor: Howard University · Participants: 30 · Started: Jul 2, 2026
Contact the study team
- Stephanie Rolin, MD MPH · Phone: (202) 865-6100
Official record on ClinicalTrials.gov — NCT07417904
Locations in the U.S.
| District of Columbia | Howard University Hospital, Washington D.C. (Not yet recruiting) Howard University Hospital, Washington D.C. |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.